The 5-/12-lipoxygenase-BLT2 cascade induces elevated expression of c-Myc, thus mediating the proliferation and migration of KRAS mutant colorectal cancer cells

References

• Cho NK, Joo YC, Wei JD, Park JI, Kim JH. 2013. BLT2 is a pro-tumorigenic mediator during cancer progression and a therapeutic target for anti-cancer drug development. Am J Cancer Res. 3:347–355.
   PubMed Web of Science ®Google Scholar
• Dews M, Tan GS, Hultine S, Raman P, Choi J, Duperret EK, Lawler J, Bass A, Thomas-Tikhonenko A. 2014. Masking epistasis between MYC and TGF-beta pathways in antiangiogenesis-mediated colon cancer suppression. J Natl Cancer Inst. 106:dju043. doi:10.1093/jnci/dju043.
   PubMedGoogle Scholar
• Dienstmann R, Connor K, Byrne AT, Consortium C. 2020. Precision therapy in RAS mutant colorectal cancer. Gastroenterology. 158:806–811. doi:10.1053/j.gastro.2019.12.051.
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, et al. 2017. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol. 28:1023–1031. doi:10.1093/annonc/mdx052.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. doi:10.1002/ijc.29210.
   PubMed Web of Science ®Google Scholar
• Gao XQ, Han JX, Huang HY, Song B, Zhu B, Song CZ. 2005. Effect of NS398 on metastasis-associated gene expression in a human colon cancer cell line. World J Gastroenterol. 11:4337–4343. doi:10.3748/wjg.v11.i28.4337.
   PubMedGoogle Scholar
• Goel A, Boland CR. 2012. Epigenetics of colorectal cancer. Gastroenterology. 143:1442–1460 e1441. doi:10.1053/j.gastro.2012.09.032.
   PubMed Web of Science ®Google Scholar
• Hennig R, Osman T, Esposito I, Giese N, Rao SM, Ding XZ, Tong WG, Buchler MW, Yokomizo T, Friess H, Adrian TE. 2008. BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation. Br J Cancer. 99:1064–1073. doi:10.1038/sj.bjc.6604655.
   PubMed Web of Science ®Google Scholar
• Hosseini SA, Zand H, Cheraghpour M. 2019. The influence of curcumin on the downregulation of MYC, insulin and IGF-1 receptors: a possible mechanism underlying the anti-growth and anti-migration in chemoresistant colorectal cancer cells. Medicina (Kaunas). 55(4):90. doi:10.3390/medicina55040090.
   Web of Science ®Google Scholar
• Ieta K, Tanaka F, Haraguchi N, Kita Y, Sakashita H, Mimori K, Matsumoto T, Inoue H, Kuwano H, Mori M. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol. 15:638–648. doi:10.1245/s10434-007-9605-3.
   PubMed Web of Science ®Google Scholar
• Ihara A, Wada K, Yoneda M, Fujisawa N, Takahashi H, Nakajima A. 2007. Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. J Pharmacol Sci. 103:24–32. doi:10.1254/jphs.FP0060651.
   PubMed Web of Science ®Google Scholar
• Kazi A, Xiang S, Yang H, Delitto D, Trevino J, Jiang RHY, Ayaz M, Lawrence HR, Kennedy P, Sebti SM. 2018. GSK3 suppression upregulates beta-catenin and c-Myc to abrogate KRas-dependent tumors. Nat Commun. 9:5154. doi:10.1038/s41467-018-07644-6.
   PubMed Web of Science ®Google Scholar
• Kim EY, Seo JM, Cho KJ, Kim JH. 2010a. Ras-induced invasion and metastasis are regulated by a leukotriene B4 receptor BLT2-linked pathway. Oncogene. 29:1167–1178. doi:10.1038/onc.2009.412.
   PubMed Web of Science ®Google Scholar
• Kim EY, Seo JM, Kim C, Lee JE, Lee KM, Kim JH. 2010b. BLT2 promotes the invasion and metastasis of aggressive bladder cancer cells through a reactive oxygen species-linked pathway. Free Radic Biol Med. 49:1072–1081. doi:10.1016/j.freeradbiomed.2010.06.023.
   PubMed Web of Science ®Google Scholar
• Kim H, Choi JA, Kim JH. 2014. Ras promotes transforming growth factor-beta (TGF-beta)-induced epithelial-mesenchymal transition via a leukotriene B4 receptor-2-linked cascade in mammary epithelial cells. J Biol Chem. 289:22151–22160. doi:10.1074/jbc.M114.556126.
   PubMed Web of Science ®Google Scholar
• Kim H, Park GS, Lee JE, Kim JH. 2013. A leukotriene B4 receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cells. Br J Cancer. 109:351–359. doi:10.1038/bjc.2013.333.
   PubMed Web of Science ®Google Scholar
• Knight JRP, Alexandrou C, Skalka GL, Vlahov N, Pennel K, Officer L, Teodosio A, Kanellos G, Gay DM, May-Wilson S, et al. 2021. Mnk inhibition sensitizes KRAS-mutant colorectal cancer to mTORC1 inhibition by reducing eIF4E phosphorylation and c-MYC expression. Cancer Discov. 11:1228–1247. doi:10.1158/2159-8290.CD-20-0652.
   PubMed Web of Science ®Google Scholar
• Korniluk A, Koper O, Kemona H, Dymicka-Piekarska V. 2017. From inflammation to cancer. Ir J Med Sci. 186:57–62. doi:10.1007/s11845-016-1464-0.
   PubMed Web of Science ®Google Scholar
• Lee JE, Lim YH, Kim JH. 2021. UCH-L1 and UCH-L3 regulate the cancer stem cell-like properties through PI3 K/Akt signaling pathway in prostate cancer cells. Anim Cells Syst (Seoul). 25:312–322. doi:10.1080/19768354.2021.1987320.
   PubMed Web of Science ®Google Scholar
• Li W, Zhu W, Lv C, Qu H, Xu K, Li H, Du Y, Liu G, Wang Y, Wei HJ, Zhao HY. 2018. Low-dose paclitaxel downregulates MYC proto-oncogene bHLH transcription factor expression in colorectal carcinoma cells. Oncol Lett. 15:1881–1887. doi:10.3892/ol.2017.7525.
   PubMed Web of Science ®Google Scholar
• Liao DJ, Thakur A, Wu J, Biliran H, Sarkar FH. 2007. Perspectives on c-Myc, Cyclin D1, and their interaction in cancer formation, progression, and response to chemotherapy. Crit Rev Oncog. 13:93–158. 016f7acc754baaa2,6431569536aac216.
   PubMedGoogle Scholar
• Magudia K, Lahoz A, Hall A. 2012. K-Ras and B-Raf oncogenes inhibit colon epithelial polarity establishment through up-regulation of c-myc. J Cell Biol. 198:185–194. doi:10.1083/jcb.201202108.
   PubMed Web of Science ®Google Scholar
• O’Brien CA, Pollett A, Gallinger S, Dick JE. 2007. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 445:106–110. doi:10.1038/nature05372.
   PubMed Web of Science ®Google Scholar
• Park J, Jang JH, Kim JH. 2019. Mediatory role of BLT2 in the proliferation of KRAS mutant colorectal cancer cells. Biochim Biophys Acta Mol Cell Res. 1866:329–336. doi:S0167-4889(18)30285-4.
   PubMed Web of Science ®Google Scholar
• Park J, Park SY, Kim JH. 2016. Leukotriene B4 receptor-2 contributes to chemoresistance of SK-OV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade. Biochim Biophys Acta. 1863:236–243. doi:10.1016/j.bbamcr.2015.11.011.
   PubMed Web of Science ®Google Scholar
• Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. 2007. Identification and expansion of human colon-cancer-initiating cells. Nature. 445:111–115. doi:10.1038/nature05384.
   PubMed Web of Science ®Google Scholar
• Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, et al. 2010. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 28:466–474. doi:10.1200/JCO.2009.23.3452.
   PubMed Web of Science ®Google Scholar
• Ruan H, Li X, Xu X, Leibowitz BJ, Tong J, Chen L, Ao L, Xing W, Luo J, Yu Y, et al. 2020. eIF4E S209 phosphorylation licenses myc- and stress-driven oncogenesis. Elife. 9. doi:10.7554/eLife.60151.
   Web of Science ®Google Scholar
• Sears RC, Nevins JR. 2002. Signaling networks that link cell proliferation and cell fate. J Biol Chem. 277:11617–11620. doi:10.1074/jbc.R100063200.
   PubMed Web of Science ®Google Scholar
• Shayimu P, Yusufu A, Rehemutula A, Redati D, Jiapaer R, Tuerdi R. 2021. MTBP promoted the proliferation, migration and invasion of colon cancer cells by activating the expression of ZEB2. Anim Cells Syst (Seoul). 25:152–160. doi:10.1080/19768354.2021.1938218.
   PubMed Web of Science ®Google Scholar
• Song J, Park S, Oh J, Kim D, Ryu JH, Park WC, Baek IJ, Cheng X, Lu X, Jin EJ. 2020. NUDT7 loss promotes Kras(G12D) CRC development. Cancers (Basel). 12: 576. doi:10.3390/cancers12030576.
   PubMed Web of Science ®Google Scholar
• Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI. 2008. Modelling Myc inhibition as a cancer therapy. Nature. 455:679–683. doi:10.1038/nature07260.
   PubMed Web of Science ®Google Scholar
• Soucek L, Whitfield JR, Sodir NM, Masso-Valles D, Serrano E, Karnezis AN, Swigart LB, Evan GI. 2013. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 27:504–513. doi:10.1101/gad.205542.112.
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhao Y, Wang X, Zhao L, Li W, Ding Y, Kong L, Guo Q, Lu N. 2016. Wogonoside prevents colitis-associated colorectal carcinogenesis and colon cancer progression in inflammation-related microenvironment via inhibiting NF-kappaB activation through PI3 K/Akt pathway. Oncotarget. 7:34300–34315. doi:10.18632/oncotarget.8815.
   PubMedGoogle Scholar
• Takahashi K, Yamanaka S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 126:663–676. doi:S0092-8674(06)00976-7
   PubMed Web of Science ®Google Scholar
• Tang Q, Chen J, Di Z, Yuan W, Zhou Z, Liu Z, Han S, Liu Y, Ying G, Shu X, Di M. TM4SF1 promotes EMT and cancer stemness via the Wnt/beta-catenin/SOX2 pathway in colorectal cancer. J Exp Clin Cancer Res. 39:232. doi:10.1186/s13046-020-01690-z.
   PubMed Web of Science ®Google Scholar
• Wei SC, Fattet L, Yang J. 2015. The forces behind EMT and tumor metastasis. Cell Cycle. 14:2387–2388. doi:10.1080/15384101.2015.1063296.
   PubMed Web of Science ®Google Scholar
• Xie QK, Chen P, Hu WM, Sun P, He WZ, Jiang C, Kong PF, Liu SS, Chen HT, Yang YZ, et al. 2018. The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor. J Transl Med. 16:273. doi:10.1186/s12967-018-1638-9.
   PubMed Web of Science ®Google Scholar
• Yang J, Guo X, Wu T, Niu K, Ma X. 2019. Prognostic significance of inflammation-based indexes in patients with stage III/IV colorectal cancer after adjuvant chemoradiotherapy. Medicine (Baltimore). 98:e14420. doi:10.1097/MD.0000000000014420.
   PubMed Web of Science ®Google Scholar
• Yokomizo T, Kato K, Hagiya H, Izumi T, Shimizu T. 2001. Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J Biol Chem. 276:12454–12459. doi:10.1074/jbc.M011361200.
   PubMed Web of Science ®Google Scholar
• Yoo MH, Song H, Woo CH, Kim H, Kim JH. 2004. Role of the BLT2, a leukotriene B4 receptor, in Ras transformation. Oncogene. 23:9259–9268. doi:10.1038/sj.onc.1208151.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li W, Nan F, Ren F, Wang H, Xu Y, Zhang F. 2011. MicroRNA expression profile of colon cancer stem-like cells in HT29 adenocarcinoma cell line. Biochem Biophys Res Commun. 404:273–278. doi:10.1016/j.bbrc.2010.11.106.
   PubMed Web of Science ®Google Scholar
• Zhang HL, Wang P, Lu MZ, Zhang SD, Zheng L. 2019a. c-Myc maintains the self-renewal and chemoresistance properties of colon cancer stem cells. Oncol Lett. 17:4487–4493. doi:10.3892/ol.2019.10081.
   PubMed Web of Science ®Google Scholar
• Zhang S, Li J, Xie P, Zang T, Shen H, Cao G, Zhu Y, Yue Z, Li Z. 2019b. Stat3/c-Myc axis-mediated metabolism alternations of inflammation-related glycolysis involve with colorectal carcinogenesis. Rejuvenation Res. 22:138–145. doi:10.1089/rej.2018.2089.
   PubMed Web of Science ®Google Scholar
• Zhong X, Lee HN, Surh YJ. 2018. RvD1 inhibits TNFalpha-induced c-Myc expression in normal intestinal epithelial cells and destabilizes hyper-expressed c-Myc in colon cancer cells. Biochem Biophys Res Commun. 496:316–323. doi:S0006-291X(17)32583-4.
   PubMed Web of Science ®Google Scholar
• Zhu G, Pei L, Xia H, Tang Q, Bi F. 2021. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer. 20:143. doi:10.1186/s12943-021-01441-4.
   PubMed Web of Science ®Google Scholar